Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir
Status:
Completed
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Sofosbuvir is the base of most treatment regimens for hepatitis C. In patients with renal
failure the blood level of one of its metabolites (GS-331007) rises up to 20 folds. Although
no particular adverse event has been linked to this metabolite sofosbuvir is not recommended
for patients with renal failure mainly because of lack of data. Nevertheless there are
anecdotal reports and small studies proving the safety of sofosbuvir in renal failure. This
study addresses this lack of information by evaluating the safety and efficacy of sofosbuvir
and daclatasvir in treating hepatitis C in 100 patients with renal failure.
Phase:
Phase 4
Details
Lead Sponsor:
Tehran University of Medical Sciences
Collaborators:
Ahvaz Jundishapur University of Medical Sciences Hamadan University of Medical Science Shiraz University of Medical Sciences